This event is in Boston, and apparently draws a few people beyond the Institutional Investors. Companies presenting include: TCRR, TCBP, CRBU, INAB, INKT, TIL Link to PR: https://www.freemindconsultants.com/2022/05/02/kisaco-octs-2022/ There is a 2nd link to see the Agenda on the link above, which asks you to submit personal information in order to download it. We are […]

This priority review is coming after an Advisory Committee voted 6-4 against it. However, the FDA does what they want after taking the Ad Coms suggestions into account. If they read the data differently, or determine there is special need for the drug on trial, they could opt to do something other than a rejection.